The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants

Youri Lee; Eun Ju Ko; Ki Hye Kim; Young Tae Lee; Hye Suk Hwang; Yu Jin Jung; Subbiah Jeeva; Young Man Kwon; Baik Lin Seong; Sang Moo Kang

doi:10.1016/j.antiviral.2019.05.011

The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants

Youri Lee, Eun Ju Ko, Ki Hye Kim, Young Tae Lee, Hye Suk Hwang, Yu Jin Jung, Subbiah Jeeva, Young Man Kwon, Baik Lin Seong, Sang Moo Kang

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Clinical trials with alum-adjuvanted formalin-inactivated human respiratory syncytial virus (FI-RSV) vaccine failed in children due to vaccine-enhanced disease upon RSV infection. In this study, we found that inactivated, detergent-split RSV vaccine (Split) displayed higher reactivity against neutralizing antibodies in vitro and less histopathology in primed adult mice after challenge, compared to FI-RSV. The immunogenicity and efficacy of FI-RSV and Split RSV vaccine were further determined in 2 weeks old mice after a single dose in the absence or presence of monophosphoryl lipid A (MPL) + CpG combination adjuvant. Split RSV with MPL + CpG adjuvant was effective in increasing T helper type 1 (Th1) immune responses and IgG2a isotype antibodies, neutralizing activity, and lung viral clearance as well as modulating immune responses to prevent pulmonary histopathology after RSV vaccination and challenge. This study demonstrates the efficacy of Split RSV as an effective vaccine candidate.

Original language	English
Pages (from-to)	100-108
Number of pages	9
Journal	Antiviral Research
Volume	168
DOIs	https://doi.org/10.1016/j.antiviral.2019.05.011
Publication status	Published - 2019 Aug

Bibliographical note

Funding Information:
This work was supported by National Institutes of Health / National Institute of Allergy and Infectious Diseases grants AI093772 , AI105170 , and AI134132 to SMK. The authors acknowledge the provision of RSV F purified proteins in post-fusion and pre-fusion conformation, and 5C4 monoclonal antibody from Dr. Barney S. Graham at Vaccine Research Center (NIAID, NIH, Bethesda, MD 20892, USA). The bacterial expression plasmid encoding RSV A2 G protein fragment (aa131-230) was kindly provided by Dr. MK Song and G protein fragment prepared by Drs. C Kim and JS Lee.

Publisher Copyright:
© 2019 Elsevier B.V.

All Science Journal Classification (ASJC) codes

Pharmacology
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.antiviral.2019.05.011

Cite this

@article{3aa94d7768da48f997d0478508523b60,

title = "The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants",

abstract = "Clinical trials with alum-adjuvanted formalin-inactivated human respiratory syncytial virus (FI-RSV) vaccine failed in children due to vaccine-enhanced disease upon RSV infection. In this study, we found that inactivated, detergent-split RSV vaccine (Split) displayed higher reactivity against neutralizing antibodies in vitro and less histopathology in primed adult mice after challenge, compared to FI-RSV. The immunogenicity and efficacy of FI-RSV and Split RSV vaccine were further determined in 2 weeks old mice after a single dose in the absence or presence of monophosphoryl lipid A (MPL) + CpG combination adjuvant. Split RSV with MPL + CpG adjuvant was effective in increasing T helper type 1 (Th1) immune responses and IgG2a isotype antibodies, neutralizing activity, and lung viral clearance as well as modulating immune responses to prevent pulmonary histopathology after RSV vaccination and challenge. This study demonstrates the efficacy of Split RSV as an effective vaccine candidate.",

author = "Youri Lee and Ko, {Eun Ju} and Kim, {Ki Hye} and Lee, {Young Tae} and Hwang, {Hye Suk} and Jung, {Yu Jin} and Subbiah Jeeva and Kwon, {Young Man} and Seong, {Baik Lin} and Kang, {Sang Moo}",

note = "Funding Information: This work was supported by National Institutes of Health / National Institute of Allergy and Infectious Diseases grants AI093772 , AI105170 , and AI134132 to SMK. The authors acknowledge the provision of RSV F purified proteins in post-fusion and pre-fusion conformation, and 5C4 monoclonal antibody from Dr. Barney S. Graham at Vaccine Research Center (NIAID, NIH, Bethesda, MD 20892, USA). The bacterial expression plasmid encoding RSV A2 G protein fragment (aa131-230) was kindly provided by Dr. MK Song and G protein fragment prepared by Drs. C Kim and JS Lee. Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2019",

month = aug,

doi = "10.1016/j.antiviral.2019.05.011",

language = "English",

volume = "168",

pages = "100--108",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier",

}

TY - JOUR

T1 - The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants

AU - Lee, Youri

AU - Ko, Eun Ju

AU - Kim, Ki Hye

AU - Lee, Young Tae

AU - Hwang, Hye Suk

AU - Jung, Yu Jin

AU - Jeeva, Subbiah

AU - Kwon, Young Man

AU - Seong, Baik Lin

AU - Kang, Sang Moo

N1 - Funding Information: This work was supported by National Institutes of Health / National Institute of Allergy and Infectious Diseases grants AI093772 , AI105170 , and AI134132 to SMK. The authors acknowledge the provision of RSV F purified proteins in post-fusion and pre-fusion conformation, and 5C4 monoclonal antibody from Dr. Barney S. Graham at Vaccine Research Center (NIAID, NIH, Bethesda, MD 20892, USA). The bacterial expression plasmid encoding RSV A2 G protein fragment (aa131-230) was kindly provided by Dr. MK Song and G protein fragment prepared by Drs. C Kim and JS Lee. Publisher Copyright: © 2019 Elsevier B.V.

PY - 2019/8

Y1 - 2019/8

N2 - Clinical trials with alum-adjuvanted formalin-inactivated human respiratory syncytial virus (FI-RSV) vaccine failed in children due to vaccine-enhanced disease upon RSV infection. In this study, we found that inactivated, detergent-split RSV vaccine (Split) displayed higher reactivity against neutralizing antibodies in vitro and less histopathology in primed adult mice after challenge, compared to FI-RSV. The immunogenicity and efficacy of FI-RSV and Split RSV vaccine were further determined in 2 weeks old mice after a single dose in the absence or presence of monophosphoryl lipid A (MPL) + CpG combination adjuvant. Split RSV with MPL + CpG adjuvant was effective in increasing T helper type 1 (Th1) immune responses and IgG2a isotype antibodies, neutralizing activity, and lung viral clearance as well as modulating immune responses to prevent pulmonary histopathology after RSV vaccination and challenge. This study demonstrates the efficacy of Split RSV as an effective vaccine candidate.

AB - Clinical trials with alum-adjuvanted formalin-inactivated human respiratory syncytial virus (FI-RSV) vaccine failed in children due to vaccine-enhanced disease upon RSV infection. In this study, we found that inactivated, detergent-split RSV vaccine (Split) displayed higher reactivity against neutralizing antibodies in vitro and less histopathology in primed adult mice after challenge, compared to FI-RSV. The immunogenicity and efficacy of FI-RSV and Split RSV vaccine were further determined in 2 weeks old mice after a single dose in the absence or presence of monophosphoryl lipid A (MPL) + CpG combination adjuvant. Split RSV with MPL + CpG adjuvant was effective in increasing T helper type 1 (Th1) immune responses and IgG2a isotype antibodies, neutralizing activity, and lung viral clearance as well as modulating immune responses to prevent pulmonary histopathology after RSV vaccination and challenge. This study demonstrates the efficacy of Split RSV as an effective vaccine candidate.

UR - http://www.scopus.com/inward/record.url?scp=85066440538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066440538&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2019.05.011

DO - 10.1016/j.antiviral.2019.05.011

M3 - Article

C2 - 31150678

AN - SCOPUS:85066440538

SN - 0166-3542

VL - 168

SP - 100

EP - 108

JO - Antiviral Research

JF - Antiviral Research

ER -

The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this